Cytoprotection: Shelter from the storm

Oncologist

Volumn 4, Issue 2, 1999, Pages 112-121

  Klein, Paula ^a   Muggia, Franco M ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AMIFOSTINE; AMINOPTERIN; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE; FOLIC ACID ANTAGONIST; FOLINATE CALCIUM; FOLINIC ACID; GEMCITABINE; GLUTATHIONE; IRINOTECAN; MESNA; METHOTREXATE; OXONIC ACID; RAZOXANE; STEROID; THYMIDINE; URIDINE;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROTECTION; CLINICAL TRIAL; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HEART PROTECTION; HISTORY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIATION PROTECTION;

EID: 0032952495     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-2-112     Document Type: Article

References (83)

1. Goldin A, Venditti JM, Kline I et al. Eradication of leukemia cells (L1210) by MTX and MTX plus citrovorum factor. Nature 1966;212:1548-1550.
2. Djerassi I, Agir E, Roger GL Jr. et al. Long-term remissions in childhood acute leukemia: use of infrequent infusions of MTX; supportive roles of platelet transfusions and citrovorum factors. Clin Pediatr 1966;5:502-509.
3. Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 1969;48:2140-2155.
4. Jaffe N, Paed D. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-1631.
5. Jaffe N, Frei E III, Traggis D et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:944-997.
6. Von Hoff DD, Rozencweig M, Louie AC et al. "Single" agent activity of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 1978;62:233-235.
7. Dorr RT. Chemoprotectants for cancer chemotherapy. Semin Oncol 1991;18(suppl 2):48-58.
8. Dorr RT, Alberts DS, Chen HSG. The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol 1988;5:17-20.
9. Dorr RT, Alberts DS. Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. Cancer Treat Rep 1981;65:1001-1006.
10. Dorr RT, Alberts DS. Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compounds. Cancer Res 1981;416:2428-2432.
11. Dorr RT, Alberts DS. Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treat Rep 1983;675:499-501.
12. Monstrey S, Mullick P, Narayanana K et al. Hyperbaric oxygen therapy and free radical production: an experimental study in doxorubicin (adriamycin) extravasation injuries. Ann Plast Surg 1997;38:163-168.
13. Dorr RT, Alberts DS, Stone A. Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep 1985;69:431-437.
14. Madhavan S, Northfelt D. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 1995;87:1556-1557.
15. Patt HM, Tyree EB, Straube RL et al. Technical papers. Cysteine protection against X irradiation. Science 1949;110:213-214.
16. Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996;23(suppl 8):2-17.
17. Yuhas JM, Storer JB. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 1969;42:331-335.
18. Glover D, Glick JH, Weiler C et al. Phase I trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1984;10:1781-1784.
19. Glick J, Glover D, Weiler R et al. Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Radiat Oncol Biol Phys 1984;10:1777-1780.
20. Kligerman M, Glover D, Turrisi A et al. Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 1984;10:1773-1776.
21. Stoller RG, Hande KR, Jacobs SA et al. Use of plasma pharmacokinetics to prevent methotrexate toxicity. New Engl J Med 1977;297:630-634.
22. Chabner BA, Young RC. Threshold methotrexate concentration for an in-vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 1973;52:1804-1811.
23. Selby PJ, Lopes N, Mundy J et al. Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy. Br J Cancer 1987;55:531-533.
24. Gore ME, Hills CA, Siddik ZH et al. Priming reduces the bone marrow toxicity of carboplatin. Eur J Cancer Clin Oncol 1987;23:75-80.
25. Howell SB, Markman M. Intraperitoneal chemotherapy: principles and results of clinical trials. In: Muggia FM, ed. Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy. Norwell, MA: Martinus Nijhoff Publishers 1987;39-63.
26. Gupta E, Safa AR, Wang X et al. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 1996;56:1309-1314.
27. Hamers FP, Brakkee JH, Cavalletti E et al. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993;53:544-549.
28. Dorr RT, Von Hoff DD. Cancer Chemotherapy Handbook. 2nd edition. Norwalk, CT: Appleton & Lange 1994;685-688.
29. Hausheer F, Kanter P, Rustum Y et al. BNP7787 - administration in vivo results in increased therapeutic index and toxicity reduction of platinum drugs. Proc Am Assoc Cancer Res 1998;39:1077a.
30. Boven E, Hulscher S, Schluper H et al. BNP7787, a new protector against platinum-toxicities, does not influence the antitumor efficacy of cisplatin or carboplatin. Proc Am Assoc Cancer Res 1998;39:1078a.
31. Blum RH. Clinical status and optimal use of the cardioprotectant dexrazoxane. Oncology 1997;11:1669-1677.
32. Chabner B, Longo D. Cancer Chemotherapy and Biotherapy. Hagerstown, MD: Lippincott-Raven, 1996:2nd Edition ;178-179.
33. Stolfi RL, Sawyer RC, Martin DS. Failure of L-histidinol to improve the therapeutic efficiency of 5-flourouracil against murine breast tumors. Cancer Res 1987;47:16-20.
34. Badary O, Mahmoud N, Al-Sawaf H et al. Effect of L-histidinol on cisplatin nephrotoxicity in the rat. Nephron 1997;77:435-439.
35. Brandes LJ, LaBella FS, Glavin GB et al. Histamine as an intracellular messenger. Biochem Pharmacol 1990;40:1677-1681.
36. Brandes LJ, LaBella FS. Histamine and calcium are independently regulated intracellular mediators of lymphocyte mitogenesis. Biochem Biophys Res Commun 1992;182:786-793.
37. Brandes LJ, Bogdanovic RP, Cawker MD et al. Histamine and growth; interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels. Cancer Res 1987;47:4025-4031.
38. Brandes LJ, Macdonald LM, Bogdanovic RP. Evidence that the antiestrogen binding site is a histamine or histamine-like receptor. Biochem Biophys Res Commun 1985;126:905-910.
39. Glavin GB, Brandes LJ. Antiulcerogenic and antisecretory effects of a novel diphenylmethamine derivative and antiestrogen binding site ligand. Can J Physiol Pharmacol 1988;66:1139-1143.
40. Glavin GB, Brandes LJ. A novel non-H1, non-H2 histamine antagonist protects against cysteamine-induced duodenal ulcers in rats. Pharmacology 1988;37:277-280.
41. Brandes LJ, LaBella FS, Warrington RC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 1991;83:1329-1336.
42. Brandes LJ, Bogdanovic RP, Cawker MD et al. Histamine and growth; interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels. Cancer Res 1987;47:4025-4031.
43. Brandes L. Proposal for a human clinical trial in small cell lung cancer of DPPE, a novel intracellular histamine antagonist which increases the therapeutic index of various cancer chemotherapy drugs. Canadian Investigational New Drug Application, HPB Control No. 7HP9M12602, HPB File No. 9427-U0198-45C, 1991.
44. Brandes L. University of Manitoba. Patent, International Publication Number WO 94/1861, 1994.
45. Brandes L, Beecroft W, Hogg G. Stimulation of in vivo tumor growth and phorbol ester-induced inflammation by N,N-diethyl-2-(4-(phenylmethyl)phenoxy) ethanamine HCl, a potent ligand for intracellular histamine receptors. Biochem Biophys Res Commun 1991;179:1297-1304.
46. Brandes L. Proposal for a human clinical trial in small cell lung cancer of DPPE, a novel intracellular histamine antagonist which increases the therapeutic index of various cancer chemotherapy drugs. Canadian Investigational New Drug Application, HPB Control No. 7HP90412602, HPB File No. 9427-U0198-45C, 1991.
47. Kudoh K, Kikuchi Y, Hiramarsu H et al. Enhancement of antitumor activity of cisplatin by N,N-diethyl-2-(4-(phenylmethyl)phenoxy)ethanamine-HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin. Eur J Cancer 1997;33:122-128, and BMS experiments numbers 391 and 433.
48. Brandes LJ, LaBella FS, Warrington RC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 1991;83:1329-1336.
49. Brandes L. University of Manitoba. Patent, International Publication Number WO 92/11035, 1992.
50. Brandes LJ, Simons KJ, Bracken SP et al. Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-4(4-phenylmethyl)phenoxy)ethanamine-HCl, in combination with various single antineoplastic agents. J Clin Oncol 1994;12:1281-1290.
51. Brandes LJ, McDonald KA, Bracken SP et al. Results of a human pilot study testing the hypothesis that the inhibitor histamine antagonist DPPE increases the therapeutic index of doxorubicin. Adv Biosci 1993;89:375-401.
52. Brandes LJ, Bracken SP, Ramsey EW. N,N-diethyl-2-(4-phenylmethyl)phenoxy) ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. J Clin Oncol 1995;12:1398-1403.
53. Brandes LJ, Simons KJ, Bracken SP et al. Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-4(4-phenylmethyl)phenoxy)ethanamine-HCl, in combination with various single antineoplastic agents. J Clin Oncol 1994;12:1281-1290.
54. Houghton JA, Houghton PJ, Woolen RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2'deoxyuridine. Cancer Res 1979;39:2406-2413.
55. Shirasaka T, Shimamota Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its anti-tumor activity in rats. J Cancer Res 1993;53:4004-4009.
56. Sorrentino BP, Brandt SJ, Bodine D et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992;254:713.
57. Hanania EG, Fu S, Roninson I et al. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR1 transcription unit. Gene Ther 1995;2:279-284.
58. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993;72(suppl):3495-3501.
59. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte-colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys 1992;22:773-779.
60. Schuchter LM, Meropol N, Glick JH. Radiation and chemotherapy protectors. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer. Principles and Practice of Oncology, 5th edition. Hagerstown, MD: Lippincott-Raven, 1997:3090.
61. Gabrilove JL, Jakubowski A, Scher H. Effect of granulocytes colony-stimulating on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-1422.
62. Grem JL, McAtee N, Murphy RF et al. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with flourouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 1994;12:560-568.
63. Chi K-H, Chen C-H, Chan W-K et al. Effect of granulocyte-macrophage colony stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, flourouracil, and leucovorin chemotherapy. J Clin Oncol 1995;13:2620-2628.
64. Muggia FM, Green MD, Speyer JL, eds. Cancer Treatment and the Heart. Baltimore: Johns Hopkins University Press, 1992.
65. Blum RH, Carter SK. Adriamycin: a new drug with significant clinical activity. Ann Intern Med 1974;80:249-259.
66. Von Hoff DD, Rozencweig M, Layard M et al. Daunomycin-induced cardiotoxicity in children and adults. Am J Med 1977;62:200-208.
67. Speyer JL, Green MD, Kramer E et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-752.
68. Swain SM, Whaley FS, Gerber MC et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997;15:1318-1340.
69. Yuhas JM, Spellman JM, Jordan SW. Treatment of tumors with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 1980;42:574-585.
70. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammine platinum (II) by WR-2721 without altering its anti-tumor properties. Cancer Treat Rep 1980;64:57-64.
71. Glover DJ, Glick JH, Weiler C et al. Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1986;12:1509-1512.
72. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-2012.
73. Takahashi I, Nagai T, Miyaishi K et al. Clinical study of the radioprotective effects of amifostine on chronic radiation injury. Int J Radiat Oncol Biol Phys 1986;12:935-938.
74. McDonald S, Meyerowitz C, Smudzin T et al. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994;29:747-754.
75. Tannehill S, Mehta M. Amifostine and radiation therapy past, present, and future. Semin Oncol 1996;23(suppl 8):69-77.
76. Van Groeningen CJ, Leyva A, Kraal I et al. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 1986;70:745-750.
77. Holm B, Jensen PB, Sehested M. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 1996;38:203-209.
78. Raghavan D. New approaches in the treatment of bladder cancer. Cancer Invest 1997;15(suppl 1):75-78.
79. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine (2,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-1534.
80. Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer; a phase II study. J Clin Oncol 1997;15:297-303.
81. Glover DJ, Glick JH, Weiler C. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986;4:584-588.
82. Delaflor-Weiss E, Blommaert F, Gill I et al. Amifostine (WR-2721) protects from bone marrow toxicity of combinations of cisplatin (P) and carboplatin (C) without decreasing platinum-DNA adduct formation. 8th NCI/EORTC Symposium on New Drugs and Cancer Therapy. 1994;214a.
83. Chen X, Herliczek TW, Keyomarsi K. Use of cell cycle checkpoint alterations to maximize therapeutic effectiveness in breast cancer. Proc Am Assoc Cancer Res 1998;39:4436a.